Does Zepbound Cause Hair Loss? Rates, When It Starts, and Whether It Grows Back
Does Zepbound cause hair loss? In trials, 4% to 5% of people reported it, and women far more often than men. When shedding starts, whether hair grows back, what helps, and when to see a doctor.
Does Zepbound cause hair loss? Yes. Hair loss is a listed common side effect of Zepbound (tirzepatide): 4% to 5% of people reported it in the label trials, compared with 1% on placebo. It was far more common in women (7.1%) than in men (0.5%) [1]. The label links it to weight reduction, and weight-loss shedding, called telogen effluvium, is usually temporary. The American Academy of Dermatology (AAD) says hair tends to regain its normal fullness within 6 to 9 months once the body readjusts [12].
Hair loss is one of several Zepbound side effects in the label. On this page you will learn:
- How common hair loss is on Zepbound, by dose and by trial
- Why it happens, and why women report it more often
- When shedding starts, how long it lasts, and whether hair grows back
- How protein, iron, and enough food fit in, and when to see a doctor
Table of Contents
- Does Zepbound cause hair loss?
- How common is hair loss on Zepbound? Rates by dose and trial
- Why Zepbound causes hair loss: rapid weight loss and telogen effluvium
- Does Zepbound cause hair loss in women? Why the rate is higher
- When does Zepbound hair loss start, and how long does it last?
- Does hair grow back after Zepbound hair loss?
- Does tirzepatide (Mounjaro) cause hair loss? How Zepbound compares with Wegovy
- How to protect your hair on Zepbound: protein, iron, and enough food
- Do biotin and hair supplements help Zepbound hair loss?
- When to see a doctor about hair loss on Zepbound
- Frequently asked questions
- Key takeaways
Does Zepbound Cause Hair Loss?
Yes. The Zepbound prescribing information lists hair loss among its most common adverse reactions, the ones reported in at least 5% of people taking Zepbound [1]. The label ties it to weight reduction.
The label's exact wording is: "Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction" [1]. So the answer to "does Zepbound cause hair loss" is yes, and the label connects it with losing weight.
Two more facts from the trials put the numbers in context:
- Severity. Canada's Zepbound product monograph states that all hair loss events with Zepbound in clinical trials were mild or moderate [3].
- Stopping treatment. No one taking Zepbound stopped the study drug because of hair loss, while one person on placebo did [1].
Mounjaro contains the same medicine, tirzepatide, but its label handles hair loss differently. The Mounjaro and Wegovy section below explains why.
How Common Is Hair Loss on Zepbound? Rates by Dose and Trial
Hair loss on Zepbound came up in 4% to 5% of people in the label's pooled trials, compared with 1% on placebo [1]. The rate did not rise with dose: 5% at 5 mg, 4% at 10 mg, and 5% at 15 mg.
| Group | People in the pool | Reported hair loss |
|---|---|---|
| Placebo | 958 | 1% |
| Zepbound 5 mg | 630 | 5% |
| Zepbound 10 mg | 948 | 4% |
| Zepbound 15 mg | 941 | 5% |
Source: Zepbound prescribing information, Table 1 (SURMOUNT-1 and -2 pooled, 72 weeks) [1]. Canada's monograph reports 5.1%, 4.2%, and 4.9% vs 0.8% [3].
ClinicalTrials.gov results for the individual SURMOUNT trials show the same pattern. Tirzepatide sits above placebo in every placebo-controlled trial that listed alopecia [4][6][7][9].
| Trial (who, reporting window) | Tirzepatide | Comparator |
|---|---|---|
| SURMOUNT-1 (obesity without diabetes, up to week 193) | 5.2% (5 mg), 5.0% (10 mg), 5.9% (15 mg) | Placebo 1.1% |
| SURMOUNT-3 (after a 12-week lifestyle program, up to week 76) | 7.0% | Placebo 1.4% |
| SURMOUNT-4 open-label lead-in (weeks 0 to 36) | 5.1% | None |
| SURMOUNT-4 double-blind (weeks 36 to 92) | 3.9% (kept taking tirzepatide) | 1.5% (switched to placebo) |
| SURMOUNT-5 (head-to-head, up to 72 weeks) | 8.3% | Semaglutide 6.1% |
| SURMOUNT-OSA (sleep apnea, up to 56 weeks) | 4.4% and 4.2% (two trials) | Placebo 0.8% and 0.9% |
Source: ClinicalTrials.gov results, queried September 30, 2026 [4][6][7][8][9].
In SURMOUNT-2, a trial in adults with type 2 diabetes, alopecia did not reach the registry's 5% reporting threshold in any group [5]. These counts are reported adverse events, not dermatologist-confirmed diagnoses. Each trial had its own population and time window, so compare them loosely.
Why Zepbound Causes Hair Loss: Rapid Weight Loss and Telogen Effluvium
The Zepbound label links hair loss to weight reduction, and the best-known type of weight-related shedding is telogen effluvium [1]. The AAD says it is normal to shed 50 to 100 hairs a day, and telogen effluvium is the medical term for shedding significantly more than that [12].
Known triggers from dermatology sources include:
- Weight loss. The AAD lists losing 20 pounds or more among the stressors that often come before excess shedding [12].
- Too little protein or food. A 2020 review names severe protein deficiency, chronic starvation, and caloric restriction as causes [14].
- Low iron stores. The same review mentions low body iron, but calls that link "very controversial" [14].
A delay separates the trigger and the shedding. One review notes that "a 3-month-lag is always present," so the cause may be over by the time hair starts to fall [13].
We found no human evidence that tirzepatide acts on hair follicles directly (PubMed search, September 30, 2026). Larger studies show an association between GLP-1 medicines and hair loss, not proof of cause:
- A meta-analysis of 9 interventional studies found a higher risk of hair loss with GLP-1 medicines than with placebo (risk ratio 3.25), with an event rate of 3.9% [16].
- A meta-analysis of observational studies found higher odds of non-scarring hair loss (odds ratio 1.40), with significant links to both telogen effluvium and pattern hair loss (androgenetic alopecia) [17].
- A 2026 BMJ study in adults with type 2 diabetes found a higher risk of non-scarring hair loss with GLP-1 medicines than with SGLT-2 inhibitors (hazard ratio 1.53). The authors called the absolute risk low [19].
Does Zepbound Cause Hair Loss in Women? Why the Rate Is Higher
Yes, and women reported hair loss on Zepbound far more often than men: 7.1% of women vs 0.5% of men, compared with 1.3% and 0% on placebo [1]. A 2026 systematic review of GLP-1 studies found the same tilt: "Females appeared to be disproportionately affected" [15].
We found no study that explains the gap. Possible contributors, none of them proven for Zepbound:
- Iron needs. Women who menstruate, especially with heavy periods, are at higher risk of low iron, and hair loss is a symptom of worsening iron deficiency anemia [21][22].
- Recent childbirth. Shedding after birth is common on its own. One review puts it at about 20% of women [13], and the AAD says it peaks about four months after giving birth [12].
- Noticing and reporting. Dermatology reviews note that women take shedding more seriously and seek care more often, while men with short hair may miss it [13][14].
Wegovy shows the same split: 4% of women vs 0.9% of men at the 2.4 mg dose [11]. Our page on Foundayo vs Zepbound compares the rates in women for both medicines.
When Does Zepbound Hair Loss Start, and How Long Does It Last?
The Zepbound trials did not track when hair loss started, so there is no trial-based onset week. A 2026 systematic review found that the time to hair loss was "not well described" in GLP-1 studies [18].
What dermatology does describe is the timeline of telogen effluvium:
- Onset. Hair loss generally shows up two to three months after the trigger [14]. The AAD says most people notice it a few months after the stressful event [12].
- Acute shedding. Lasts less than six months [14].
- Chronic shedding. Lasts more than six months [13][14].
- Ongoing triggers. The AAD notes that if the stressor stays with you, shedding can be long lived [12].
Weight loss on Zepbound builds gradually over many months, as our page on how long Zepbound takes to work shows. So shedding may begin a few months into treatment and continue while weight is still coming off. That is an inference from the telogen effluvium timeline, not a Zepbound trial finding.
Does Hair Grow Back After Zepbound Hair Loss?
Hair usually grows back after weight-loss shedding. The AAD says that as the body readjusts, shedding stops, and hair tends to regain its normal fullness within six to nine months [12]. No Zepbound trial measured regrowth, so this timeline comes from dermatology, not from the Zepbound label.
Two signs point away from simple shedding:
- Bald patches. A dermatology review describes telogen effluvium as excess shedding without hairless patches [13].
- Thinning at the part or crown that does not recover. This can be a different condition, such as androgenetic alopecia, which an observational meta-analysis also linked to GLP-1 use [17].
A dermatologist can examine your scalp and sort out which type of hair loss you have. Regrowth is likely but not guaranteed, especially while the trigger continues.
Does Tirzepatide (Mounjaro) Cause Hair Loss? How Zepbound Compares With Wegovy
Tirzepatide is the medicine in both Zepbound and Mounjaro, so the Zepbound trial data describe tirzepatide itself. The Mounjaro label lists alopecia only among postmarketing reports. Those reports come from a population of uncertain size, so it is not always possible to reliably estimate their frequency [10].
Hair loss does not appear in Mounjaro's table of common adverse reactions [10]. Our page on Zepbound vs Mounjaro covers the other differences between the two brands.
Wegovy (semaglutide) also lists hair loss:
- Wegovy 2.4 mg: 3.3% vs 1% on placebo (4% of women, 0.9% of men) [11].
- Wegovy 7.2 mg: 5.8% vs 1.0% on placebo (8.4% of women, 0.2% of men) [11].
- SURMOUNT-5, head-to-head: 8.3% on tirzepatide vs 6.1% on semaglutide [8]. Its planned outcomes were weight measures, so side effects were recorded but not a tested comparison.
The two labels draw on different trials and populations, so their rates are not directly comparable. Our page on Zepbound vs Wegovy compares the two medicines in full.
How to Protect Your Hair on Zepbound: Protein, Iron, and Enough Food
We found no study showing that any treatment prevents hair loss on Zepbound. The best-supported step is to avoid under-eating while weight comes off, since severe protein shortfall and caloric restriction are known triggers of telogen effluvium [14].
Protein is the first place to look. A 2025 joint advisory from four medical and nutrition societies notes that targets of 1.2 to 1.6 grams per kilogram of body weight a day have been proposed during active weight loss [20]. It also says it is unclear whether to base these targets on actual, adjusted, or ideal body weight. Our page on how much protein to eat on a GLP-1 works through the numbers. If you want high-protein recipes and meal ideas sized for a smaller appetite, see our GLP-1 meal plan and protein guide.
When appetite is low, a practical approach (general advice, not a Zepbound trial finding) is smaller meals that start with the protein part of the plate, plus snacks such as eggs, Greek yogurt, fish, or beans. The joint advisory notes that smaller, more frequent meals can help ease nausea [20]. Our page on a GLP-1 meal plan shows how to plan meals this way.

Iron matters too, especially for women. MedlinePlus lists 18 mg a day for women 19 to 50, 8 mg a day from age 51, and 27 mg a day in pregnancy [21]. Women who menstruate, especially with heavy periods, are at higher risk of low iron [21]. Good sources include eggs, lean red meat, poultry, salmon, tuna, dried beans, and iron-fortified cereals.
Finally, watch for signs of eating too little. The joint advisory names excessive hair loss as a sign of nutrient deficiency, along with unusual fatigue, muscle weakness, and poor wound healing [20]. It warns that intake under 1,200 kcal a day for women raises the risk of falling short on vitamins and minerals [20].
Do Biotin and Hair Supplements Help Zepbound Hair Loss?
We found no evidence that biotin or hair supplements help Zepbound hair loss. A dermatology review of telogen effluvium states: "The literature does not support either vitamin E or biotin supplementation" [13].
Biotin can also cause a separate problem. FDA warns that biotin "can significantly interfere with certain lab tests and cause incorrect test results which may go undetected" [23]. If you take biotin or a "hair, skin and nails" product, tell your clinician before any blood work.
Prescription hair treatments, such as minoxidil, are something a dermatologist can discuss with you.
When to See a Doctor About Hair Loss on Zepbound
See your prescriber or a dermatologist if Zepbound hair loss looks different from diffuse shedding or does not settle. The Zepbound Medication Guide says: "Talk to your healthcare provider if you have any side effect that bothers you or that does not go away" [2].
Book a visit if you notice any of these:
- Bald patches or hairless spots
- Scalp pain, redness, or scarring
- Shedding that lasts longer than 6 months
- Signs of iron deficiency, such as feeling weak or tired more than usual or dizziness, especially with heavy periods [22]
- Signs of eating too little, such as unusual fatigue, skin flakiness, muscle weakness, poor wound healing, or unusual bruising [20]
- Hair loss together with other new symptoms
Talk to your prescriber before changing how you take Zepbound. The AAD advises: "If you suspect that a treatment or drug is causing your hair loss, talk with your doctor. Serious side effects can occur if you immediately stop a treatment or drug" [12].
You can also report side effects to FDA at 1-800-FDA-1088 [2].
Frequently Asked Questions
Does Zepbound hair loss grow back?
Usually. The AAD says hair tends to regain its normal fullness within 6 to 9 months once the body readjusts. No Zepbound trial measured regrowth.
How soon does hair loss start on Zepbound?
The trials did not track onset. Telogen effluvium generally starts two to three months after its trigger, so shedding may begin a few months into treatment.
Is hair loss on Zepbound worse at higher doses?
The label does not show that: 5% at 5 mg, 4% at 10 mg, and 5% at 15 mg, vs 1% on placebo. Your prescriber decides your dose.
Should I stop Zepbound if my hair is falling out?
Talk to your prescriber first. The AAD warns that serious side effects can occur if you stop a treatment or drug immediately. No one on Zepbound stopped for hair loss in the label trials.
Does biotin help hair loss on Zepbound?
The dermatology literature does not support it, and FDA warns that biotin can interfere with some lab tests.
Why do women lose more hair on Zepbound?
We found no study that explains it. Iron needs with periods, recent childbirth, and noticing shedding more are possible contributors, none of them proven.
Does Zepbound or Wegovy cause more hair loss?
In SURMOUNT-5, 8.3% on tirzepatide vs 6.1% on semaglutide reported hair loss, but its planned outcomes were weight measures, so side effects were not a tested comparison.
Key Takeaways
- Yes, it is a listed side effect. About 4% to 5% of people on Zepbound reported hair loss in trials, vs 1% on placebo, with no rise at higher doses.
- Women report it more. The rate was 7.1% in women vs 0.5% in men.
- The label links it to weight loss. Telogen effluvium usually starts a few months after the trigger.
- Hair usually grows back. The AAD says fullness tends to return within 6 to 9 months.
- Eat enough, and ask before changing anything. Bald patches or shedding past 6 months need a doctor.
This article is for education only, is not medical advice, and gives no personalized dosing advice. Read our full medical disclaimer.
References
- Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
- Zepbound Medication Guide, revised 08/2026: Eli Lilly
- Zepbound Product Monograph, Canada, date of authorization 2026-06-11: Eli Lilly Canada
- SURMOUNT-1 results, NCT04184622: ClinicalTrials.gov
- SURMOUNT-2 results, NCT04657003: ClinicalTrials.gov
- SURMOUNT-3 results, NCT04657016: ClinicalTrials.gov
- SURMOUNT-4 results, NCT04660643: ClinicalTrials.gov
- SURMOUNT-5 results, NCT05822830: ClinicalTrials.gov
- SURMOUNT-OSA results, NCT05412004: ClinicalTrials.gov
- Mounjaro (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
- Wegovy (semaglutide) Prescribing Information, revised 06/2026: Novo Nordisk
- Do you have hair loss or hair shedding? American Academy of Dermatology
- Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol, 2019
- Asghar F et al. Telogen effluvium: a review of the literature. Cureus, 2020
- Gupta AK et al. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Sci Prog, 2026
- Cheng PL, Chang HC. GLP-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract, 2026
- Viquez Burboa GU et al. GLP-1 receptor agonists and alopecia: systematic review and meta-analysis. Skin Appendage Disord, 2026
- Branyiczky MK et al. Effects of GLP-1 receptor agonists on hair loss and regrowth: a systematic review. Int J Dermatol, 2026
- Tang H et al. Risk of hair loss associated with GLP-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ, 2026
- Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025
- Iron in diet: MedlinePlus, National Library of Medicine
- Iron deficiency anemia: MedlinePlus, National Library of Medicine
- Biotin interference with troponin lab tests: U.S. Food and Drug Administration